Faculty & Staff Scholarship
2017

Altering calcium influx for selective destruction of breast tumor
Han-Gang Yu
West Virginia University

Sarah McLaughlin
West Virginia University

Mackenzie Newman
West Virginia University

Kathleen Brundage
West Virginia University

Amanda Ammer
West Virginia University

See next page for additional authors

Follow this and additional works at: https://researchrepository.wvu.edu/faculty_publications

Digital Commons Citation
Yu, Han-Gang; McLaughlin, Sarah; Newman, Mackenzie; Brundage, Kathleen; Ammer, Amanda; Martin,
Karen; and Coad, James, "Altering calcium influx for selective destruction of breast tumor" (2017). Faculty
& Staff Scholarship. 1765.
https://researchrepository.wvu.edu/faculty_publications/1765

This Article is brought to you for free and open access by The Research Repository @ WVU. It has been accepted
for inclusion in Faculty & Staff Scholarship by an authorized administrator of The Research Repository @ WVU. For
more information, please contact beau.smith@mail.wvu.edu.

Authors
Han-Gang Yu, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin,
and James Coad

This article is available at The Research Repository @ WVU: https://researchrepository.wvu.edu/faculty_publications/
1765

Yu et al. BMC Cancer (2017) 17:169
DOI 10.1186/s12885-017-3168-x

RESEARCH ARTICLE

Open Access

Altering calcium influx for selective
destruction of breast tumor
Han-Gang Yu1* , Sarah McLaughlin2, Mackenzie Newman1, Kathleen Brundage2,3, Amanda Ammer2,
Karen Martin2,4 and James Coad5

Abstract
Background: Human triple-negative breast cancer has limited therapeutic choices. Breast tumor cells have depolarized
plasma membrane potential. Using this unique electrical property, we aim to develop an effective selective killing of
triple-negative breast cancer.
Methods: We used an engineered L-type voltage-gated calcium channel (Cec), activated by membrane depolarization
without inactivation, to induce excessive calcium influx in breast tumor cells. Patch clamp and flow cytometry were
used in testing the killing selectivity and efficiency of human breast tumor cells in vitro. Bioluminescence and
ultrasound imaging were used in studies of human triple-negative breast cancer cell MDA-MB-231 xenograft in
mice. Histological staining, immunoblotting and immunohistochemistry were used to investigate mechanism that
mediates Cec-induced cell death.
Results: Activating Cec channels expressed in human breast cancer MCF7 cells produced enormous calcium influx at
depolarized membrane. Activating the wild-type Cav1.2 channels expressed in MCF7 cells also produced a large calcium
influx at depolarized membrane, but this calcium influx was diminished at the sustained membrane depolarization due
to channel inactivation. MCF7 cells expressing Cec died when the membrane potential was held at -10 mV for 1 hr,
while non-Cec-expressing MCF7 cells were alive. MCF7 cell death was 8-fold higher in Cec-expressing cells than
in non-Cec-expressing cells. Direct injection of lentivirus containing Cec into MDA-MB-231 xenograft in mice
inhibited tumor growth. Activated caspase-3 protein was detected only in MDA-MB-231 cells expressing Cec, along
with a significantly increased expression of activated caspase-3 in xenograft tumor treated with Cec.
Conclusions: We demonstrated a novel strategy to induce constant calcium influx that selectively kills human
triple-negative breast tumor cells.
Keywords: Breast cancer, Triple-negative, Bioelectricity, Calcium channel, Selective killing, Caspase-3

Background
One of the biggest challenges in breast cancer treatment
is the non-selective destruction of healthy cells alongside
cancer cells. There are three major clinically identifiable
types of breast cancer: estrogen receptor (ER+) and/or
progesterone receptor (PR+) positive, human epidermal
growth factor receptor 2 amplified (HER2-amplified), and
triple-negative (no alterations of ER, PR, and HER2). The
intracellular signaling pathways that underlie these subtypes of breast cancer are different and as a result
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chemotherapeutics that target one pathway will be effective in only some of the breast cancer subtypes [1].
Altered bioelectricity during cell division, embryogenesis,
and development has been recognized [2]. In vivo impedance measurement of female breasts with and without
tumors revealed lower resistance in malignant tumors than
in normal mammary tissues [3]. In excised normal and
malignant breast tissues, the conductivity is higher in
malignant tissues [4]. In breast tissue cells from patients
with infiltrating ductal carcinoma, the resting membrane
potential (Em) was found to be −13 mV, independent of
estrogen receptor (ER) or progesterone receptor (PR)
presence [5]. Normal human breast epithelial cell Em is
near -60 mV [5].
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Calcium influx has increasingly been recognized to
play a critical role in breast cancer [6]. Cell proliferation
depends on external Ca2+, and a fine-controlled Ca2+ influx through voltage-gated calcium channel (VGCC) is a
critical signal in cell proliferation [7, 8]. Under physiological conditions, there exists a 20,000 - fold Ca2+ ion
gradient across plasma membrane ([Ca2+]o is close to
2 mM, [Ca2+]i is around 100nM) [9]. Thus, calcium influx via VGCC becomes a critical cell signal for a variety
of cell functions such as neurotransmission, muscle contraction and cell growth [10].
VGCC have been categorized into Cav1 family (L-type),
Cav2 family (N-, P/Q and R-type), and Cav3 family
(T-type), based on their biophysical, pharmacological
and structural properties [10]. VGCC are found in excitable cells such as neuronal, skeletal muscle and cardiac
cells, but are not present in non-excitable healthy human
mammary epithelial cells [11]. In primary tumor from patients and breast cancer cell lines Cav3.2 transcripts and
protein expression have been detected [12–14]. Cav3 Ttype calcium channels have a much faster inactivation
compared to Cav1 L-type channels [10]. The brief calcium
influx through Cav3.2 T-type channel inactivation in
response to depolarization is an essential signal for
breast cancer cell growth since blockade of this T-type
channel dramatically reduced proliferation of breast
cancer cells [14].
The amount of calcium ions entering cells is tightly
controlled by voltage-dependent activation and inactivation of VGCC [15, 16]. Disturbance of VGCC gating can
significantly change the amount of external calcium ions
entering cell. Excessive Ca2+ influx has been demonstrated to induce apoptosis and cell death [9, 17, 18].
VGCC are activated by membrane depolarization [10].
However, during sustained membrane depolarization
Ca2+ entry is limited by channel inactivation, an intrinsic
protection mechanism [19, 20]. When the channel inactivation is removed, continuous Ca2+ influx leading to
excessive accumulation of intracellular Ca2+ ions can be
generated.
We have recently demonstrated that altering bioelectricity and external calcium concentration can induce
death of different types of breast cancer cells, MCF7
and MDA-MB-231 [21]. In the present work, we
demonstrated that using an engineered VGCC that
lacks inactivation (Cec) [22], massive Ca2+ influx can
be induced to trigger the death of human carcinoma
breast tumor cells, but not in non-tumor human mammary epithelial cells. Cec injected into a human breast
tumor in vivo caused cell death within the tumor via
caspase-3 and inhibited tumor growth. This approach
of selective killing of human breast cancer cells is
independent of ER+/PR+, HER2 and triple-negative
subtypes.
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Methods
Human mammary non-tumor and cancer cell lines were
purchased from American Tissue Culture Center (ATCC)
(non-tumor cells MCF10A, CRL-10317; MCF7 cell line,
HTB-22; MDA-MB-231 cell line: HTB-26).
Cell culture and plasmid transfection

Human breast adenocarcinoma cells (ER-positive MCF7,
triple-negative MDA-MB-231/Luc) and human mammary gland epithelial cells (MCF10A) were grown in
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen),
supplemented with 10% fetal bovine serum, 100 IU/mL
penicillin, and 100 g/L streptomycin. Normal human
mammary epithelial cells (HMEC) were grown in
mammary epithelial cell basal medium (MEC), supplemented with MEC growth kit (ATCC). For patch
clamp studies, HMEC and MCF7 cells were grown on
poly-D-lysine coated coverslips in DMEM and MEC,
respectively.
Cells with 50–70% confluence in 6-well plates were
used for transient plasmid transfection (1–2 μg for
each plasmid). We used three methods for plasmid
transfection: Lipofectamine2000 transfection reagent
(Invitrogen), MCF7 transfection reagent (Altogen) and
Nucleofection (electroporation, Lonza).
Cav1.2 and Cec, both in pCEP4 mammalian expression vector, were either co-transfected with GFP or fused
with mCherry for verification of expression and served
as selection guidance for patch clamp studies and flow
cytometry experiments. The beta subunit of Cav1.2, β2a,
was co-transfected with Cav1.2 and Cec to enhance the
surface expression of the channel proteins [16].
Patch clamp studies

From day 1 up to day 4 post-transfected cells with green
fluorescence were selected for patch clamp studies. The
cells grown on coverslips were placed in a lucite bath
with the temperature maintained at 35–37 °C. Em and
voltage-gated calcium currents were recorded using the
whole cell patch clamp technique with an Axopatch700B amplifier. Em was measured with normal Tyrode
and pipette solutions. The Tyrode solution contained
(in mM): 143 NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 0.25
NaH2PO4, and 5 HEPES; pH was adjusted to 7.4 by
NaOH. The pipette solution contained (in mM): 120
KCl, 1 CaCl2, 5 MgCl2, 5 Na2ATP, 11 EGTA, 10
HEPES, and 11 glucose; pH was adjusted to 7.3 by
KOH.
For ICaL recordings, the pipettes had a resistance of
2–5 MΩ when filled with (in mM): 108 CsCl, 4 MgCl2,
9 EGTA, and 9 HEPES. The bath solution contained
(in mM): 2 CaCl2, 1 MgCl2, 10 HEPES, 10 TEA, 10
glucose, and 100 CsCl. Both pipette and bath solutions
were adjusted by CsOH to pH 7.2. P/4 protocols were
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used to remove the leak currents [23]. The whole-cell
patch clamp data were acquired by CLAMPEX and analyzed by CLAMPFIT (pClamp 9, Molecular Device/Axon).
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human breast adenocarcinoma cells (MDA-MB-231/Luc,
1-2×106 cells/animal) were injected into the fourth inguinal mammary gland of 6- to 8-week-old mice. Primary
tumors had formed one week of injection.

Live cell imaging

Live cell imaging experiments were performed using a
Zeiss Axio Observer A1 inverted microscope with fluorescence. Images were acquired and analyzed using AxioVision (version 4.6). Live cell imaging with patch clamp
experiments were performed using Slidebook (version 4.0).
We used ethidium homodimer-1 (EthD-1, Invitrogen) dye
(0.2–0.5 μl of 2 mM stock to 1 ml culture of cells in 6-well
plate) to label dead cells. EthD-1 dye enters the cell only
after the plasma membrane is disintegrated, it then
binds to DNA in the nucleus and emits red fluorescence (Invitrogen) [24].

Primary tumor imaging

Animals were anesthetized by exposure to 1–3% isoflurane during imaging. Imaging was performed weekly over
the course of each experiment, typically for 4–6 weeks.
Tumor size measurement by bioluminescence imaging (BLI)

D-Luciferin (150 mg/kg) was injected into the peritoneum. Images were obtained after ten minutes’ exposure
using an IVIS Lumina-II Imaging System and Living
Image-4.0 software (PerkinElmer). Luciferin-sensitive bioluminescence signals (photons/s) were used to assess the
tumor size.

Flow cytometry

Cell death was examined using a Live/Dead Fixable
Violet Viability kit (Life Technologies) following the
manufacturer’s instructions. Briefly, cells were transfected and cultured as described above. After trypsinization and washing, cell pellets were resuspended in PBS
and stained with the Live/Dead dye in the kit. Samples
were then analyzed on a BD LSRFortessa analytical flow
cytometer (BD Biosciences, San Jose CA) using BD Diva
8.0 software. The GFP signal was detected using a
488 nm sapphire laser and a 530/30 BP filter in front of
the detector. The Violet live/dead signal was detected
using a 405 nm OBIS laser and a 450/50 BP filter in
front of the detector. Between 25,000 and 30,000 events
were collected for each sample.
Lentivirus preparation

Cec was inserted into a GFP tagged lentiviral vector,
pCDH-CMV-MCS-EF1-GFP + Puro (System Biosciences,
SBI) between SwaI and NotI in MCS to yield lenti-GFPCec plasmid. The empty lentiviral vector fused with GFP
(lenti-GFP) was used as a negative control. Lentivirus
was produced using pPACK lentivector packaging systems following the vendor’s instruction manual (SBI).
The concentration of lentivirus was 1-2×1012 LP/ml (LP:
lentiviral particle). For treatment groups, 5-10ul of lentiGFP-Cec was injected directly into the primary tumor.
For control groups, 5–10ul of lenti-GFP was injected
directly into the primary tumor. The same amount of
virus was administrated to each group per experiment.

Tumor volume measurement by ultrasound imaging (USI)

Tumor volume was imaged by Vevo2100 MicroUltrasound System. A 40 or 50 mHz transducer was
used, depending on the tumor volume. A 3-dimensional
(3D) image was acquired with scanning distance of
0.071 mm between images. Vevo software then integrated the images into a reconstructed 3D tumor from
which the tumor volume was obtained.
Tumor fluorescence imaging

Tumor imaging was performed with an Olympus
MVX10 MacroView microscope in conjunction with
cellSens software version 1.11. Images were acquired
using a 1X objective at 0.8X zoom. Bright field images
were rendered at around 20 ms exposure in 16-bit grayscale, while fluorescence was captured at around 700 ms
in 8-bit RGB mode. Image overlays were converted to 8bit RGB color before analysis.
Histology of NSG tumors

Primary tumors were removed from NSG mice, fixed in
4% (m/v) formaldehyde for 16 hrs and embedded in paraffin. Paraffin blocks were cut to 5-μm-thick sections for
hematoxylin and eosin (H&E) stain. Imaging of H&E
slides was performed with an Olympus MVX10 MacroView microscope equipped with dual cameras, Hamamatsu (fluorescence imaging) and DP26 (color imaging).
Necrotic area was quantified using ImageJ (NIH).
Western blotting

Breast tumor induction in NOD scid gamma (NSG) mice

Female NSG-immunodeficient mice were purchased
from the Jackson Laboratory. Animals were housed in the
WVU Animal Facility under protocols approved by the
Institutional Animal Care and Use Committee. For mammary pad injections, pathogen-free luciferase-expressing

MDA-MB-231 cells were and transfected with either a
lentiviral GFP construct, wild-type Cav1.2, Cec, or empty
vector as a control. After three days of incubation, adherent cells were lysed in buffer (20 mM Tris, 150 mM
NaCl, 10 mM EGTA, and 10 mM EDTA at pH ~ 7.4)
with a cell scraper and allowed to sit for five minutes.

Yu et al. BMC Cancer (2017) 17:169

Detached cells were pelleted and resuspended in the
lysis solution. After centrifugation at 3,000xg for five minutes, supernatant protein concentration was measured
using Bradford's method.
SDS-PAGE was carried out in 4–12% gradient bis-tris
gels (Invitrogen) on 10–20 μg of total protein. Samples
were then transferred to 0.2 μm pore PVDF membranes
(Thermo Scientific). After blocking with 3% BSA-V
(Sigma) in TBST (Invitrogen), caspase-3 antibody (Abcam)
was added in a 1:1000 dilution and left to incubate overnight at 4 °C, followed by incubation with secondary antibody in a 1:5000 dilution. After one hour, membranes were
washed five times for five minutes in TBST and visualized
using a standard ECL kit (Life Technologies).
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by 1 mM Mn2+ and 0.1 mM Ni2+ ions [10, 26] (dotted
line in Fig. 1b).
Properties of L-type VGCC and engineered channel (Cec)
expressed in MCF7 cells

Immunohistochemistry (IHC) detection of cleaved caspase3 in formalin-fixed paraffin-embedded (FFPE) tumor tissue
was performed according to vendor’s manual instruction
(Biocare) and following a verified protocol in the Pathology
Laboratory of Translational Medicine at WVU. Briefly,
3 μm sections were deparaffinized on slides, quenched with
hydrogen peroxide, and incubated in cleaved caspase-3
antibody (prediluted rabbit polyclonal antibody, Biocare
Medical, Concord, CA, 1:200 dilution) at 4 °C for 4 min.
Horseradish peroxidase-containing secondary antibody
(UMap anti-RB, Roche, Diagnostic, Cupertino, CA) was
then added for 8 min and developed using Biocare DAB
(brown color). Hematoxylin was used as a counterstain
(blue color).
Caspase-3 IHC slides were examined under an Olympus
AX70 Provis microscope equipped with an Optronics
MicroFire color CCD camera and a 20x/0.70 UPlanApo
objective or a 40x/0.90 UApo objective. Images were acquired using Stereo Investigator 10 (MDF Bioscience).
Quantification of cells expressing cleaved caspase-3 was
performed by ImageJ [25].

L-type calcium channels are activated at a depolarized
Em, around -40 mV associated with 10–100 times slower
inactivation compared to T-type calcium channel [10].
Cav1.2 L-type calcium channel was co-transfected with
GFP into MCF7 cells. L-type calcium current (ICaL, ICav1.2)
was elicited by a 500 ms depolarizing pulse to -10 mV
(Fig. 1c). Inactivation of ICaL is significantly slower compared to that of ICaT (or ICav3.1) (Fig. 1b) (note the different
time scales used in 1b and 1c). L-type calcium current was
verified by a specific L-type calcium channel blocker,
verapamil (10 μM) (dotted line in Fig. 1c).
Cec, an engineered Cav1.2 channel with defective inactivation, was expressed in MCF7 cells. Cec current (ICec)
was activated by a 500 ms depolarizing pulse to -10 mV
(Fig. 1d). Cec has the same activation as Cav1.2 but lacks
inactivation, i.e. the current trace does not come back to
the baseline, as T-type and wild-type L-type calcium currents do. Cec channel has a similar current–voltage
relationship as Cav1.2 (Fig. 1e).
Calcium influx through voltage-gated calcium channels is indicated by the gray lines enclosed by the
current trace and the dotted baseline (Fig. 1b, c, d). In
response to a 500 ms depolarizing pulse to -10 mV from
a holding potential of -80 mV, Cec induced more than a
50,000-fold larger amount of calcium influx than was induced by endogenous T-type channels in MCF7 cells
(Ca-flux_HMEC: 0.001 ± 0.001 pA*ms; CaT-flux_MCF7:
0.24 ± 0.15 pA*ms; Cav1.2-flux_MCF7: 24.0 ± 3.8 pA*ms;
Cec-flux_MCF7: 53.8 ± 5.1 pA*ms; Fig. 1f ). Under the
same pulse protocol, Cav1.2 induced more than a 20,000fold higher calcium influx compared to T-type calcium
channel (Fig. 1f).

Statistical analysis

Cec-induced cell death in MCF7 cells

Data were shown as mean ± standard deviation (SD) in
the text. Bar figures were presented as mean ± SD
using GraphPad 4 (Prism). Student’s t-test and twoway ANOVA (for more than two groups) were used for
statistical analysis. P < 0.05 was considered as statistically significant.

A dramatic increase in calcium influx is lethal to cell
survival. To test whether excessive calcium influx
through Cec channels can indeed trigger cell death, we
activated Cec while simultaneously monitoring the cell’s
status using fluorescence imaging. Figure 2a shows a
Cec-expressing MCF7 cell clamped by a patch pipette.
Figure 2b shows three neighboring Cec-expressing cells
that were not patch clamped. Figure 2c shows the naturally dead cells stained by Ethd-1 (red color), which contrast the patched live cell shown in the white circle.
After holding the cell membrane at–10 mV for 1 h, the
patched cell was dead as indicated by the appearance of
red color (Fig. 2d). Figure 2e shows the same image with
increased exposure time for clarity. Death of the patched
cell was confirmed by disappearance of GFP and the

Immunohistochemistry of NSG tumors

Results
Voltage-gated calcium currents in normal and tumor
mammary epithelial cells

Patch clamp studies confirmed absence of voltage-gated
calcium currents in normal HMEC cells (Fig. 1a) and
only T-type voltage-gated calcium current (ICaT) in
MCF7 cells (Fig. 1b). T-type calcium current was verified
by its fast activation and inactivation as well as blockage

Yu et al. BMC Cancer (2017) 17:169
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Fig. 1 Ca2+ influx through L-type voltage-gated calcium channels in breast cancer cells. a Lack of voltage-gated calcium currents in response
to the 500 ms depolarizing pulses from -50 mV to +50 mV in 10mv increments (inset). b Representative T-type calcium current in a MCF7 cell
(inset is the pulse protocol). c After 3-day transfection of Cav1.2 in MCF7 cells, L-type calcium current was elicited by a 500 ms depolarizing
pulse to -10 mV; gray lines show the Ca2+ influx. d After 1-day transfection of Cec, L-type calcium current was elicited by a 500 ms depolarizing pulse
to -10 mV. Gray lines in the enclosed area in b, c, and d indicate the Ca2+ influx. e Normalized current–voltage (IV) relationship of L-type Cav1.2 (ICaL)
and Cec expressed in MCF7 cells (n = 6 in each group), the membrane potential was held at -80 mV. f Ca2+ influx generated by T-type calcium current,
L-type calcium current, and Cec calcium current in response to a 500 ms depolarizing pulse to -10 mV, respectively (n = 6). * indicates statistical
significance compare to ICa in MCF7 and in HMEC groups. The membrane potential was held at -80 mV

survival of its neighboring cells which also expressed
Cec but were not voltage-clamped at–10 mV (Fig. 2f
versus Fig. 2b). Cells co-expressing Cav1.2 and GFP
under the same experimental conditions showed no sign
of dying (Figs. 2g–i).
To examine the efficacy of Cec-induced cell death, we
compared the percent of cell death in GFP-expressing or
Cec-expressing MCF7 cells using flow cytometry. After
3 days of transfection, Cec induced significantly more
cell death (Fig. 3b) than GFP alone (Fig. 3a) in both
GFP(−) and GFP(+) populations (upper left and upper
right quadrants). In the absence of Ca2+ ions, the flow
cytometry results were similar in Cec-expressing and
non-Cec-expressing cells (Fig. 3c, d). On an average,
there was a 9-fold increase in GFP(+) dying cells in Cecexpressing than in GFP-expressing MCF7 cells (Fig. 3e)
(GFP(+) dead were 18.3 ± 8.6% in Cec-expressing cells

and 1.7 ± 0.7% in GFP-expressing cells, respectively, n = 6).
In addition, GFP(−) cell death was increased by 8-fold in
Cec-expressing (58.8 ± 10.5%) than in GFP-expressing
(6.9 ± 6.6%) MCF7 cells (n = 6). It should be noted that
GFP(−) dead cells included both untransfected cells and
Cec-expressing cells that have degraded GFP protein.
When calcium was removed from the culture medium,
there was no statistically significant difference in percentage of cell death between GFP-expressing and Cecexpressing groups (Fig. 3f ) (GFP(+) dead were 1.2 ± 1.2%
in Cec-expressing cells and 2.2 ± 2.7% in GFP-expressing
cells, n = 6). The percentage of cell death in GFP(−) dead
in Cec-expressing cells was also significantly decreased
when Ca2+ was absent (74.7 ± 12.7% in the presence of
Ca2+ and 16.1 ± 7.8% in the absence of Ca2+, n = 6).
MCF10A (a non-tumorigenic human breast epithelial
cell line) cells have been commonly used as a control to

Yu et al. BMC Cancer (2017) 17:169
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Fig. 2 Depolarization-triggered cell death in a single Cec-expressing MCF7 cell. a After 1 day transfection a Cec-expressing cell was clamped by a
patch pipette. b A focused region of four Cec-expressing cells showing green fluorescence. c Ethd-1 was used to stain dead cells. Note that the
patched cell in a white circle was live (no red color) prior to membrane depolarization. d After 1 h of depolarizing membrane to -10 mV, the patched
cell was dead shown by the red color in the white circle. e Enhanced exposure to illustrate the red color in the white circle. f In comparison to (b) the
dead cell was confirmed by loss of green fluorescent signal while other 3 Cec-expressing cells not subjected to membrane depolarization were still
alive. g A Cav1.2-expressing MCF cell patched by a patch pipette, h Ethd-1 demonstrated that the patched cell was alive (in the white circle), the white
arrows indicated dead cells used as a reference. i After membrane depolarization to -10 mV for 1 h, the cell was still alive without the red color. White
circle in H and I indicates the patched cell. Similar results were obtained in an additional 5 cells

MCF7 cells [27]. We found the resting membrane potential of MCF10A to be −53.5 ± 8.2 mV (n = 4), in
agreement with a previous report [5]. Flow cytometry results showed that in Ca2+ - containing culture medium,
there is no statistically significant difference between GFPexpressing cells and Cec + GFP expressing cells (Fig. 3g).
(GFP(+) dead were 3.7 ± 3.1% in Cec-expressing cells and
5.3 ± 3.0% in GFP-expressing cells, n = 3).
Cec-induced inhibition of tumor growth in NSG mice

To further explore whether Cec-mediated Ca2+ influx
can inhibit breast tumor growth in vivo, we used a commonly used human breast tumor mouse model, NOD
scid gamma (NSG) mice. The xenograft tumors in NSG
were induced by injection of MDA-MB-231/Luc cells.
MDA-MB-231 is a human breast triple-negative cancer
cell line [28]. The resting membrane potential was measured to be −39.48 ± 12.14 (n = 7), similar to MCF7.
After three weeks of tumor growth, lentivirus injection
was performed. Control mice were injected with lentiGFP and treatment mice were injected with lenti-GFPCec directly into the tumor. To confirm the presence of
lentivirus within the tumor after injection, the primary
tumor was removed and subjected to fluorescence

imaging. Figure 4a shows the absence of GFP fluorescence within a tumor which received no injection of
lentivirus. No GFP fluorescence was observed in tumors
injected by lenti-GFP-Cec, presumably due to the cell
death. Tumors injected with lenti-GFP showed GFP
fluorescence (Fig. 4b, white arrow; Fig. 4c – enlarged
GFP image). Similar observation was seen in at least
three control mice.
Tumor size was measured by bioluminescence imaging
(BLI) illustrated in 4D (control mouse) and 4E (treatment mouse). Changes BLI for control and treatment
groups are shown in Fig. 4f. Lentivirus injection was performed in week 3. There are no statistically significant
changes in BLI between the two groups until week 5. At
week 5, the tumor size was 70% smaller in treatment
group (0.5 ± 0.2 (photons/s) ×109, n = 6) compared to control group (1.69 ± 0.79 (photons/s) ×109, n = 4, p = 0.007).
In treatment group, BLI was also decreased by 53% at
week 5 (0.5 ± 0.2 (photons/s) ×109) compared to week 4
(1.06 ± 0.32 (photons/s) ×109, p = 0.015).
Figure 5 shows the tumor volume measured by ultrasound imaging (USI). For the first four weeks there are
no statistical differences in tumor volumes between the
control and treatment groups (p > 0.05). At week 5,

Yu et al. BMC Cancer (2017) 17:169
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Fig. 3 Cec-induced cell death from flow cytometry. a MCF7 cells transfected with only GFP in DMEM containing 1.8 mM Ca2+. b MCF7 cells
co-transfected with GFP and Cec in DMEM containing 1.8 mM Ca2+. c MCF7 cells transfected with only GFP in DMEM without Ca2+. d MCF7 cells
co-transfected with GFP and Cec in DMEM without Ca2+. e Percentage of dead cells between GFP-expressing and Cec-expressing MCF7 groups
in the presence of Ca2+, * indicates p < 0.001 in all three groups (n = 6). f Percentage of dead cells between GFP-expressing and Cec-expressing
MCF7 groups in the absence of Ca2+, p > 0.05 in all three groups (n = 5). g Percentage of dead cells between GFP-expressing and Cec-expressing
MCF10A cells, p > 0.05 in all three groups (n = 5)

tumor volume was 37% smaller in the treatment group
than in the control group (control: 1240 ± 379 mm3, n = 3,
treatment: 776 ± 112 mm3, n = 5, p < 0.05) (5a). From
week 4 to week 5, the tumor grew by 158% in control
group (week 4: 480 ± 251 mm3, week 5: 1240 ± 379 mm3,
n = 3, p < 0.05), whereas the tumors grew 46% in the treatment group (week 4: 533 ± 146 mm3, week 5: 776 ±
111 mm3, n = 5, p < 0.05) (5a). Over 3-fold slower growth
in treatment group was due to the smaller change in
volume compared to control group from the previous
week (for difference between week 4 and week 5,
control = 760 mm3; treatment = 243 mm3) (5b).
Cec-induced cell death within MDA-MB-231 xenograft

Hematoxylin & eosin (H&E) staining was performed for
Cec-treated (6a) and control (6b) tumors. Close to 23%
of area within the control tumors was dead (22.6 ±
15.2%, n = 4) and nearly 76% of area within the treated
tumors was dead (75.7 ± 5.3%, n = 4) (6c).

Concerning naturally occurred necrosis in large tumors (defined as the volume greater than 200 mm3,
length greater than 7 mm), we also examined dead or
dying cells in small tumors (defined as the volume less
than 200 mm3, length less than 7 mm). Nitro blue tetrazolium (NBT) staining indicated that dead/dying cells
were visible in a typical small tumor injected with Ceccontaining lentivirus (6d, dash yellow line), but barely
detected in the small tumor injected with control lentivirus (6e). Although the average tumor volume was similar between the two groups (V_treat = 164.1 ± 90.0 mm3,
V_control = 132.9 ± 131.6 mm3, n = 3, p > 0.05), the percent growth of tumor is 7-fold smaller in treat group
(26.7 ± 23.9%) than in control group (201.5 ± 123.8%)
(6 F, n = 3, p < 0.05).
Excessive Ca2+ influx induced by Cec can trigger apoptosis commonly mediated by caspase activation [9].
Among several caspases present in the MDA-MB-231
cells, caspase-3 is the most commonly activated one in
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Fig. 4 Fluorescence imaging of primary tumors, tumor size assessment by bioluminescence imaging. a Primary tumor without virus injection.
b Primary tumor injected with lenti-GFP control virus. Yellow arrow indicates the GFP signal. c Enlarged GFP fluorescence from B. The control
group (dark bar) was injected with lenti-GFP and the treatment group (white bar) was injected with lenti-GFP-Cec. The lentivirus injection was
performed at week 3. BLI was taken weekly for the control mouse (d) and the treated mouse (e) from week 2 to week 5. f BLI signals, total flux
(photons per second), were shown for control group (n = 3) and for treatment group (n = 5). * indicates significant difference compared to the
control group at week 5

response to a variety of anti-cancer drugs that induce
cell death [29–31]. The active caspase-3 protein expression was detected only in MDA-MB-231 cells expressing
Cec, but absent in cells expressing control vector (GFP)
and untransfected (N) cells (6 g). In small MDA-MB231 xenograft tumors, the cleaved (active) caspase-3
expressing cells was barely detected (5.4 ± 3.0% in untreated and 14.3 ± 4.0% GFP treated group, respectively,
n = 4) (6 h, j), but significantly expressed in Cec-treated
group (50.4 ± 19.0%, n = 4) (6i, j).

Discussion
Excessive negative charges at the external surface of
plasma membranes due to lower K+ concentration and
higher Na+ concentration in cancer cells was observed
nearly 50 years ago [32, 33]. As a result, the resting plasma
membrane potential is depolarized in cancer cells. The
intrinsic link between membrane depolarization and

tumorigenesis has been elegantly illustrated by mitosis in
mature neurons induced by sustained depolarization [34].
Depolarization can activate a variety of ion channels
that elicit multiple cell functions. One of these ion channels is a voltage-gated calcium channel [20]. Ca2+ influx
following the opening of VGCC is a critical signal for
cell proliferation [9]. Recently, membrane depolarization
has been recognized as an early bioelectric signal which
can serve as a diagnostic marker for cancer development, as hyperpolarization was shown to inhibit tumor
formation [35].
We found a significant membrane depolarization in
MCF7 and MDA-MB-231 cells compared to normal
HMEC, in agreement with previous observations both in
cell lines and primary tumors [5]. It is noted that use of
whole-cell patch clamp technique offers advantages over
microelectrode measurement of tissue for accurate measurements of plasma membrane potential [36]. We also
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Fig. 5 Tumor volume weekly measured by ultrasound imaging.
The lentivirus injection was performed at week 3. The control
group (dark bar) was injected with lenti-GFP and the treatment
group (white bar) was injected with lenti-GFP-Cec. Tumor volume
is shown in (a) and tumor volume change is shown in (b). The inset in
(a) shows the drawing contour of the tumor, the inset in (b) shows the
3D reconstitution of the tumor. The volume change was calculated by
dV(n) = Vn – V (n-1), where n = 1 to 5. Data were averaged from 3
control mice and 5 treated mice. * indicates significant difference
compared to the control group at week 5

found no voltage-gated calcium currents in normal
mammary epithelial cells, but T-type calcium currents in
MCF7 cells with a typical voltage-dependent activation
from -70 mV to +40 mV (Figs. 1c, d). These results support the notion that T-type calcium current serves as a
functional biomarker in human breast cancer cells.
To test our hypothesis for selectively killing of breast
cancer cells by inducing excessive Ca2+ influx, we chose
Cav1.2 because it is not present in either HMEC or
MCF7 cells [11, 37] (Fig. 1b). Cav1.2 began to activate at a
membrane potential more positive than -40 mV, +30 mV
more positive than T-type calcium current activation
threshold. Thus, introducing Cav1.2 into cells should not
alter cell function unless the cell is depolarized to -40 mV.
In comparison to Cav1.2, Cec has a similar activation
threshold (Fig. 1h) but the inactivation current trace was
unable to return to baseline (Fig. 1g), leading to defective
closure of the channel. As a result, external calcium ions
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can constantly enter the cell. For a 500 ms depolarizing
pulse, opening of Cec channels allowed more than a
50,000-fold higher amount of calcium influx compared to
T-type calcium channels (Fig. 1j). We noted that Cav1.2
channels can also induce more than a 20,000-fold higher
amount of calcium influx over T-type calcium channels
(Fig. 1j). The difference between Cav1.2 and Cec, however,
is that Cav1.2 channels can close (becoming inactivated)
during sustained membrane depolarization, while Cec
cannot.
At single-cell level, we showed that the Cec-expressing
cells died when the membrane was held at -10 mV for an
hour (Fig. 2d–f). Neighboring Cec-expressing cells that
were not depolarized to -10 mV did not die (Fig. 2b, f).
This experiment demonstrated the selectivity of Cecmediated killing of cancer cells. It also revealed difficulty
in killing cancer cells expressing the Cav1.2 channel
(Fig. 2g–i). Although opening of Cav1.2 can induce more
than a 20,000-fold amount of Ca2+ influx compared to
non-Cav1.2 expressing cells, the cells did not die due to
inactivation of the channel.
The killing of MCF7 cells via a Cec-induced increase
in Ca2+ influx was further tested in cell monolayer. Flow
cytometry data (Fig. 3) confirmed that Cec activation
can indeed kill MCF7 cells but not MCF10A cells and
that Ca2+ is the critical factor in Cec-mediated cell
death.
To verify whether the results obtained in vitro work
in vivo, we injected 1-2 × 106 MDA-MB-231/Luc cells
into 6–8 weeks old female NSG mice. Primary tumor
can grow to 0.1–0.3 mm3 volumes after 2–3 weeks,
which allows direct injection of virus into the primary
tumor (Fig. 3a-c). The tumor volumes were assessed and
measured by bioluminescence and ultrasound imaging,
respectively. There is a noticeable difference in tumor
measurements using BLI and USI. Two weeks after virus
injection (at week 3), BLI showed a decrease in tumor size
(Fig. 4f), whereas USI showed continuing growth of
the tumors (although at a slower rate) (Fig. 5b). This difference may be due to two different imaging mechanisms. BLI signals depend on luciferin binding to
luciferase in MDA-MB-231 tumor cells. Dead or dying
cells cannot yield BLI signals due to disrupted luciferase
structure, but they contribute to the aggregate anatomical
structure captured by USI. Nevertheless, both BLI and
USI measurements demonstrated consistent results:
comparing to the control mice, tumor growth in the
treatment group was significantly inhibited by Cec. This
conclusion is further confirmed by histological examination demonstrating that the Cec-induced inhibition of
tumor growth was a direct consequence of markedly increased cells death within the tumor (Fig. 6).
Apoptosis is most commonly mediated by caspase
activation [9]. MDA-MB-231 cells have at least four
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Fig. 6 Cec-induced cell death in NSG tumors. Tumors at week 6 were removed. H&E staining was performed in a treated tumor (a) and a control
tumor (b). c Percentage of dead cells in control and treat mice. Tumors at week 3.5 were removed. Live/dead NBT (nitro blue tetrazolium)
staining was performed in a treated tumor (d) and in a control tumor (e). Yellow dash line indicates live (a) or dead cells (b, d). f Percent growth
of treated and control tumors. * indicates statistical significance in comparison to the control tumor. g The pro-caspase was detected in MDA-MB-231
cells near 36 kDa (N for non-transfection). The active caspase appeared around 20 kDa in cells expressing Cec but not GFP (another negative control)
or non-transfection (N). GAPDH was used as the loading controls. Cleaved caspase-3 expression (cells in brown color) is shown in untreated small
tumor (yellow arrows) (h) and in Cec-treated small tumor (i), respectively. j Percentage of caspase-3 expression cells in untreated or treated with empty
lentiviral vector and Cec-treated small tumors. * indicates statistical significance comparing to untreated or GFP treated tumor

isoforms of caspases (caspase-3, −6, −8, −9) [31]. We
found that the activated caspase-3 expression was detected only cells expressing Cec (Fig. 6g), in agreement
with a high prevalence of cleaved caspase-3 in MDAMB-231 xenograft tumors treated by Cec (Figs. 6i, j).
Thus, the Cec-induced cell death is at least partially
medicated by activation of caspase-3.

Limitations of this research in clinical perspective

This work was focused on proof-of-concept of finding a
way to treat breast cancer independent of subtypes. It is
imperative to point out the limitations of this research
in clinical implication. Calcium influx is a vital signal in
many physiological activities such as neuronal action potential, heartbeat, and muscle contraction. Disruption of
delicate intracellular calcium concentration can cause
mental, cardiac, and muscle disorders. Thus, this research can only be applied locally in mammary tissue to
avoid global adverse effects. Additionally, efficiency of
introducing Cec into mammary epithelial cells in vivo
has yet to be tested, although in cell culture lentiviral
particles that contain Cec can achieve over 95%

transfection rate. These limitations are the driving forces
in future direction of this research.

Conclusions
In conclusion, we presented data that supports a new
strategy for selectively triggering tumor cell death: excessive Ca2+ influx induced only in the depolarized plasma
membranes of breast cancer cells. This strategy is independent of subtypes of breast cancer and may have a
therapeutic application in triple-negative breast cancer
that currently lacks targeted therapies.
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